BRPI0416933A - composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e, métodos para aumentar a respiração mitocondrial em um paciente, e para reduzir a quantidade de espécies de oxigênio reativas em um paciente - Google Patents

composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e, métodos para aumentar a respiração mitocondrial em um paciente, e para reduzir a quantidade de espécies de oxigênio reativas em um paciente

Info

Publication number
BRPI0416933A
BRPI0416933A BRPI0416933-6A BRPI0416933A BRPI0416933A BR PI0416933 A BRPI0416933 A BR PI0416933A BR PI0416933 A BRPI0416933 A BR PI0416933A BR PI0416933 A BRPI0416933 A BR PI0416933A
Authority
BR
Brazil
Prior art keywords
compound
patient
disease
pharmaceutical composition
methods
Prior art date
Application number
BRPI0416933-6A
Other languages
English (en)
Inventor
Preben H Olesen
Thomas Kruse Hansen
Lise Brown Christiansen
Holger Claus Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BRPI0416933A publication Critical patent/BRPI0416933A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Color Printing (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO PARA TRATAR UMA DOENçA, USO DE UM COMPOSTO, E, MéTODOS PARA AUMENTAR A RESPIRAçãO MITOCONDRIAL EM UM PACIENTE, E PARA REDUZIR A QUANTIDADE DE ESPéCIES DE OXIGêNIO REATIVAS EM UM PACIENTE". As novas anilidas salicílicas são decopuladores químicos úteis, por exemplo, para o tratamento de obesidade.
BRPI0416933-6A 2003-11-25 2004-05-04 composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e, métodos para aumentar a respiração mitocondrial em um paciente, e para reduzir a quantidade de espécies de oxigênio reativas em um paciente BRPI0416933A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301738 2003-11-25
US52637803P 2003-12-01 2003-12-01
PCT/DK2004/000304 WO2005051894A1 (en) 2003-11-25 2004-05-04 Novel salicylic anilides

Publications (1)

Publication Number Publication Date
BRPI0416933A true BRPI0416933A (pt) 2007-01-16

Family

ID=34635235

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416933-6A BRPI0416933A (pt) 2003-11-25 2004-05-04 composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e, métodos para aumentar a respiração mitocondrial em um paciente, e para reduzir a quantidade de espécies de oxigênio reativas em um paciente

Country Status (11)

Country Link
US (2) US7645791B2 (pt)
EP (1) EP1689700A1 (pt)
JP (1) JP2007513880A (pt)
KR (1) KR20060101500A (pt)
AU (1) AU2004293133A1 (pt)
BR (1) BRPI0416933A (pt)
CA (1) CA2545023A1 (pt)
IL (1) IL175154A0 (pt)
NO (1) NO20062832L (pt)
RU (1) RU2006116421A (pt)
WO (1) WO2005051894A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255240A1 (en) * 2004-05-05 2008-10-16 Novo Nordisk A/S Sulfonamide Derivatives
EP1888508A2 (en) * 2005-05-23 2008-02-20 Novo Nordisk A/S Novel haloalkoxy-substituted salicylic anilides
EP1888513A1 (en) * 2005-05-23 2008-02-20 Novo Nordisk A/S Novel trifluoromethoxy-substituted aryl anilides
AU2007284801A1 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
EP2097391A1 (en) * 2006-11-15 2009-09-09 High Point Pharmaceuticals, LLC 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes
ATE523497T1 (de) 2006-11-15 2011-09-15 High Point Pharmaceuticals Llc Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
US7939690B2 (en) 2006-11-15 2011-05-10 High Point Pharmaceuticals, Llc Haloalkylsulfone substituted compounds useful for treating obesity and diabetes
EP2086951B1 (en) 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
PT2593452T (pt) 2010-07-14 2017-04-24 Novartis Ag Compostos heterocíclicos agonistas do receptor ip
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
WO2018129258A1 (en) 2017-01-06 2018-07-12 Gencia Corporation Novel phenyl derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34102C (de) TH. GARE in Stockpprt Cheshire, England Neuerungen an Maschinen zum Zurechtschneiden, Poliren, Ausfertigen und Putzen von Stiefeln oder Schuhen
CH281901A (de) * 1950-04-25 1952-03-31 Hoffmann La Roche Verfahren zur Herstellung eines neuen Tropasäureabkömmlings.
GB728098A (en) * 1952-03-05 1955-04-13 Geigy Ag J R Improvements relating to salicylanilides and their use
GB1153994A (en) * 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
GB1493375A (en) * 1974-09-20 1977-11-30 Ici Ltd Salicylanilide derivatives
US4673691A (en) 1984-11-05 1987-06-16 Nicholas Bachynsky Human weight loss inducing method
JP2668231B2 (ja) 1987-12-29 1997-10-27 大日精化工業株式会社 電子写真感光体
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
CA2337690C (en) 1998-07-27 2013-10-01 Texas Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
JP3937200B2 (ja) * 1998-09-10 2007-06-27 三井化学株式会社 新規な遷移金属錯体、オレフィン重合用触媒およびオレフィンの重合方法
WO2001007028A2 (en) * 1999-07-23 2001-02-01 Allergan Sales, Inc. The use of retinoid receptor antagonists in the treatment of prostate carcinoma
US20020052343A1 (en) 1999-12-15 2002-05-02 Allen Darin Arthur Salicylamides as serine protease inhibitors
WO2001082924A1 (en) 2000-05-02 2001-11-08 Smithkline Beecham Corporation Phosphate transport inhibitors
US6790569B2 (en) 2000-06-13 2004-09-14 Eastman Kodak Company Color photothermographic elements comprising phenolic thermal solvents
CN101103977A (zh) * 2002-06-05 2008-01-16 株式会社医药分子设计研究所 糖尿病治疗药
EP1535610A4 (en) * 2002-06-10 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC CANCER
US20040138301A1 (en) * 2002-11-08 2004-07-15 Hansen Birgit Sehested Chemical uncouplers for the treatment of obesity

Also Published As

Publication number Publication date
EP1689700A1 (en) 2006-08-16
AU2004293133A1 (en) 2005-06-09
IL175154A0 (en) 2006-09-05
NO20062832L (no) 2006-06-16
KR20060101500A (ko) 2006-09-25
US20100075932A1 (en) 2010-03-25
CA2545023A1 (en) 2005-06-09
WO2005051894A1 (en) 2005-06-09
JP2007513880A (ja) 2007-05-31
US7645791B2 (en) 2010-01-12
RU2006116421A (ru) 2008-01-10
US20090005434A1 (en) 2009-01-01

Similar Documents

Publication Publication Date Title
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
ECSP034732A (es) Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
TW200633695A (en) Methods for purifying trans-(-)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
GB0420888D0 (en) Compounds and uses
BRPI0416933A (pt) composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e, métodos para aumentar a respiração mitocondrial em um paciente, e para reduzir a quantidade de espécies de oxigênio reativas em um paciente
BRPI0405166A (pt) Composição de cuidados pessoais e processo para preparar a mesma
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
CY1108633T1 (el) Κοσμητικη συνθεση βασεως σουκραλφατ και θειικων αλατων χαλκου και ψευδαργυρου
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
FR2863169B1 (fr) Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BRPI0211635B8 (pt) composto ciclo-hexil-sulfona, uso do mesmo, e, composição farmacêutica
BR0213317A (pt) Uso de um composto, método de tratar um distúrbio relacionado com gastrina, composição farmacêutica, kit, usos de uma composição, e de um inibidor de bomba de próton, métodos de preparar uma composição farmacêutica e um composto, e, composto
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: HIGH POINT PHARMACEUTICALS, LLC (US)

Free format text: TRANSFERIDO DE: NOVO NORDISK A/S

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.